DEF: Third Harmonic Bio to Dissolve, Seeks Stockholder Approval for Liquidation Plan

Third Harmonic Bio announces plans to dissolve the company and distribute remaining cash to stockholders, pending stockholder approval at the upcoming annual meeting.

Summary

• Third Harmonic Bio is seeking stockholder approval to liquidate and dissolve the company.
• The decision follows a strategic review where the Board determined dissolution is in the best interest of stockholders.
• The company estimates an initial distribution between $5.13 and $5.33 per share.
• The Annual Meeting is scheduled for June 5, 2025, where stockholders will vote on the dissolution plan.
• The Board of Directors may abandon or delay implementation of the Plan of Dissolution, even after stockholder approval.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company is dissolving, the plan aims to return value to shareholders, which is a positive outcome in a challenging situation. However, there are risks and uncertainties associated with the process.

Positives

• The Board of Directors believes that the Dissolution is in the best interests of the Company and our stockholders.
• The company intends to continue THB335 development activities through the first half of 2025 to maximize the proceeds to shareholders that may be obtained in a potential asset sale.

Negatives

• The amount distributed to stockholders may be less than currently estimated due to liabilities, obligations, and expenses.
• Stockholders may not be able to recognize a loss for U.S. federal income tax purposes until they receive a final distribution.
• The Board of Directors may turn management of the liquidation over to a third party, and some or all of our directors may resign from our Board of Directors at any time.

Risks

• The amount distributed to stockholders may be substantially less than the current estimate if liabilities, obligations, and expenses are higher than anticipated.
• The payment of the distribution to stockholders could be delayed due to claim settlements with creditors.
• Stockholders could be held liable for payment to creditors if the contingency reserve is inadequate.
• The Board of Directors may abandon or revoke the Dissolution, which may cause prior distributions to be treated as dividends.
• The Dissolution will require a change in the basis of accounting, which could result in write-downs of certain assets.

Future Outlook

The company intends to make an initial distribution as soon as practicable following the effectiveness of the filing of the Certificate of Dissolution. The timing and amount of the distribution will depend upon the actual expenses incurred, the timing of the resolution of matters for which we have established the contingency reserve and the amount to be paid in satisfaction of such contingencies.

Management Comments

• Natalie Holles, Chief Executive Officer, invites stockholders to attend the 2025 Annual Meeting.
• The Board of Directors has determined that the Dissolution is advisable and in the best interests of the Company and our stockholders.

Industry Context

Given the challenging biotech funding environment, Third Harmonic Bio's decision to dissolve and return capital to shareholders reflects a growing trend of companies prioritizing capital preservation and strategic alternatives.

Comparison to Industry Standards

• Other biotech companies facing similar challenges, such as Tricida, Inc. and IMARA Inc., have also explored strategic alternatives, including potential sales or mergers.
• The estimated distribution of $5.13 to $5.42 per share is a key metric for investors to compare against potential returns from alternative strategic options.
• The decision to dissolve and return capital is a strategic choice that some companies have made when facing challenges in clinical development or market access, as opposed to continuing operations with uncertain prospects.

Related Party Transactions

• The company has a license agreement with Novartis, a holder of more than 5% of its outstanding common stock, involving milestone payments and royalties.

Stakeholder Impact

• Stockholders will receive distributions from the liquidation of the company.
• Employees have been affected by workforce reductions as part of the restructuring.
• The company will terminate any of our remaining commercial agreements, relationships or outstanding obligations.

Next Steps

• Stockholders to vote on the Dissolution Proposal at the Annual Meeting on June 5, 2025.
• If approved, the company will file a Certificate of Dissolution with the Delaware Secretary of State in the third quarter of 2025.
• The company will then proceed with the liquidation and distribution of assets to stockholders.

Key Dates

Keywords

dissolution, liquidation, stockholders, THB335, distribution, annual meeting, board of directors, strategic review, assets, liabilities